Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 7Terminated 2Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoblastic Lymphadenopathy 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Sezary Syndrome 1Recurrence 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1Anemia, Aplastic 1

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × Alemtuzumab × Clear all
NCT00363090 2013-09-20

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
84 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡